Page results
-
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCLH, UCL and the Francis Crick Institute.
-
This page tells you about having a Non-Tunnelled CVC Line Insertion (Vascath). This page is for those patients who have been referred to Interventional Radiology.
-
This page tells you about having a PICC (Peripherally Inserted Central Catheter) line insertion with the Interventional Radiology team.
-
This booklet tells you about having a Vortex® Port-a-cath Insertion (implantable port) with the Interventional Radiology team.
-
This page tells you about having a PICC (Peripherally Inserted Central Catheter) line insertion with the Vascular Access team.
-
This page is for patients who have been referred by their GP to a gynaecology specialist because their symptoms need further tests.
-
A research team involving UCLH clinicians has found a way to reduce the side effects of treatment for a disorder of the adrenal glands.
-
Mr George Attilakos is a consultant in obstetrics and fetal medicine and the clinical lead for obstetrics at UCLH. Alongside managing normal pregnancies, Mr Attilakos has a special interest in the management of multiple pregnancies and high-risk pregnancies, as well as expertise in fetal medicine and fetal surgery, including in-utero treatment for congenital diaphragmatic hernia, spina bifida and twin-to-twin transfusion syndrome.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
This page is for patients who have been referred on a suspected cancer pathway.
File results
-
FOI/2023/0300 - Post-mortem examinations for 2019, 2020, 2021 and 2022
-
FOI/2023/0301 - Meat served at the Trust that may contain nitrates or nitrites
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0295 - Strikes and Trust use of the BMA rate card
-
FOI/2023/0315 - Menopause Lead at the Trust